CLOs on the Move

Medexus

www.medexus.com

 
Leading North American Specialty Pharmaceutical Company focused on hematology, rheumatology, auto-immune disease, specialty oncology and pediatrics.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.medexus.com
  • 35 Nixon Road Unit 1
    Bolton, ON CAN L7E 1K1
  • Phone: 877.633.3987

Executives

Name Title Contact Details

Similar Companies

Alvogen

Alvogen is a multinational, privately owned pharmaceuticals company focused on developing, manufacturing and distributing generic, brand, over-the-counter brands (OTC) and biosimilar products. With more than 200 pharmaceutical projects in development and registration, the group`s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of: oncology, cardiology, respiratory, neurology and gastroenterology. Alvogen has commercial operations in over 30 countries with 2,000 employees. North America is Alvogen`s single largest market and other key markets include: South-Korea, Romania, Bulgaria, Hungary, Taiwan, Russia and China.

Gastro Care Partners

Gastro Care Partners is the national partner for successful regional gastroenterology practices. We equip practices with the resources necessary to thrive.

Validation Resources

Validation Resources is a Bend, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Theradex Oncology Experts

Theradex is an international contract research organization providing complete professional services for the clinical research and development of pharmaceutical compounds, medical devices and diagnostic tests in the areas of oncology and

Walking Fish Therapeutics

Walking Fish Therapeutics, Inc. is a privately held biotechnology company discovering and developing innovative therapeutics that harness the power of B cells as protein factories and immune modulators. Walking Fish has created a broad technology platform addressing enzyme replacement therapies, oncology, autoimmune disease, and recombinant antibody production. The company`s first program, WFX-001, employs B cells as protein factories to generate a deficient enzyme in Fabry disease. Founded in 2019 by Lewis (Rusty) Williams, MD, PhD, the former CSO of Chiron, co-founder of Cor Therapeutics and founder and Chief Executive Officer of Five Prime Therapeutics, the company has assembled a diverse and experienced team of scientists and business leaders who are committed to bringing life-changing and life-saving therapeutics to patients worldwide.